non-muscle invasive bladder cancer

Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy

Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...